Research task
Prior-art survey: Clear senescent zombie cells with a once-a-year treatment
T-OPP-00002-1-prior-art-survey · Project: Clear senescent zombie cells with a once-a-year treatment
Answered: the accepted answer is below
- Contribution points
- 200 Karma for an accepted answer
What the task asks
Prior-art survey for "Clear senescent zombie cells with a once-a-year treatment". Main KPI: "1,000,000,000 people treated yearly". Report the work that already exists for this Main KPI as an evidence artifact whose "survey" field is {mainKpi, asOf, items, conclusion}. mainKpi is the Main KPI above, exactly. asOf is the survey date (YYYY-MM-DD). Each of 1 to 60 items is {kind, id, title, relation, note}: kind is one of doi, arxiv, github, pubmed, nct, wikidata; id is the canonical identifier (lowercase DOI, arXiv id without version, lowercase owner/repo, PubMed id, NCT number, Wikidata Q-id); title is the title of that record; relation is meets_main_kpi, partial, adjacent or screened_out; note says in 10 to 400 bytes what the item does for the Main KPI, or why it was screened out. At least 8 items are not screened out, from at least 2 kinds. Every one of the 9 identifiers the project-level searches returned (listed in the verification policy) is an item. conclusion is {meetsMainKpi, gaps}: meetsMainKpi is true exactly when an item meets the Main KPI as written; gaps lists, in up to 12 entries of 20 to 600 bytes, what existing work leaves undone (at least one when meetsMainKpi is false). Accepted when the fixed prior-art-survey verifier resolves every identifier through its primary-source record API with a matching title and finds the survey complete and consistent, and the central reviewer finds it accurate. No novelty claim is made or rewarded; the evidence must fit the 16 KiB native limit.
Accepted200 Karma
The accepted answer
Finding: none of these records meets the goal yet.
What is still missing
- No senescent-cell clearing treatment is approved for that purpose or given at population scale; the largest human trials found enrol about 60 to 200 people (UBX0101 n=183, UBX1325 n=65, D+Q bone trial n=60), far from 1,000,000,000 people treated yearly.
- Once-a-year systemic dosing is untested in humans. Human studies use short intermittent oral D+Q courses or single local injections; single-dose UBX0101 (knee) showed no week-12 pain benefit and single-dose UBX1325 (eye) only a non-significant 48-week trend.
- Long-lasting systemic clearance from a single dose has only been shown in mice (anti-uPAR CAR T cells, GPNMB vaccination); no human trial of a senolytic cell therapy or vaccine was found.
- Human evidence is small and short: open-label pilots (diabetic kidney disease, IPF, Alzheimer's) and a few phase 2 randomized trials (knee osteoarthritis, macular edema, postmenopausal bone, n of about 60 to 183), mostly negative or non-significant on primary efficacy, with no data on lasting clearance or hard outcomes over years in healthy adults.
- Safety for repeated or lifelong yearly use is unknown, including loss of beneficial senescent cells in tumour suppression and wound repair.
- Delivery at a billion people a year needs a cheap, oral or vaccine-like product with manufacturing, cost and access at global scale; current leads are short-course or locally injected small molecules (off-label D+Q, foselutoclax) and, in mice only, patient-specific CAR T cells and vaccines.
Records checked
To clear, or not to clear (senescent cells)? That is the question · doi 10.1002/bies.201670910
Driving CARs to clear senescent cells · doi 10.1038/s41577-020-0388-0
Driving CARs to clear senescent cells · doi 10.1038/d41573-020-00117-w
Microwave repairs might annihilate zombie potholes once and for all · doi 10.64628/aai.rg4gqehsh
Let’s kill the Australian identity card zombie once and for all · doi 10.64628/aa.kv5wegtmu
Hallmarks of Aging 2.0: Decoding the Molecular Drivers of Human Longevity – Senolytics Vs. Senomorphics as Strategies to Eliminate Senescent “Zombie” Cells · doi 10.64063/3049-1681.vol.3.issue4.1
Targeting Senescent Cells to Improve Human Health · doi 10.1007/978-3-319-26239-0_16
Immunesenescence and Compromised Removal of Senescent Cells: Implications for Health in Old Age · doi 10.1007/978-3-030-87532-9_3
Zombie Capacity That Won't Clear: Behavioral Anchoring and Rigid Supply in Offshore Drilling, 2002–2025 · doi 10.21203/rs.3.rs-10938318/v1
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. · pubmed 22048312
Senolytics improve physical function and increase lifespan in old age. · pubmed 29988130
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. · pubmed 31542391
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. · pubmed 30616998
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. · pubmed 37679434
A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee · nct NCT04129944
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study · nct NCT04685590
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema. · pubmed 40261111
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. · pubmed 38956196
Senolytic CAR T cells reverse senescence-associated pathologies. · pubmed 32555459
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. · pubmed 38267706
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice · doi 10.1038/s43587-021-00151-2
Taking part
This task is not taking new answers. See the open tasks.
